Kynurenine hydroxylase and kynureninase inhibitors as tools to study the role of kynurenine metabolites in the central nervous system

Advances in Experimental Medicine and Biology

Volumn 398, Issue , 1996, Pages 203-210

  Moroni, F ^a   Carpenedo, R ^a   Chiarugi, A ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG DERIVATIVE; ENZYME INHIBITOR; HYDROLASE; KYNURENINASE; KYNURENINE; KYNURENINE 3 MONOOXYGENASE; MIXED FUNCTION OXIDASE;

ANIMAL; CENTRAL NERVOUS SYSTEM; DRUG ANTAGONISM; DRUG DESIGN; DRUG EFFECT; HUMAN; KINETICS; METABOLISM; PHYSIOLOGY; REVIEW; STRUCTURE ACTIVITY RELATION;

ANIMALS; CENTRAL NERVOUS SYSTEM; DRUG DESIGN; ENZYME INHIBITORS; HUMANS; HYDROLASES; KINETICS; KYNURENINE; KYNURENINE 3-MONOOXYGENASE; MIXED FUNCTION OXYGENASES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0030346562     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4613-0381-7_33     Document Type: Article

References (22)

1. Bender DA, McCreanor GM (1982) The preferred route of kynurenine metabolism in the rat. Biochim Biophys Acta 717:56.
2. Carpenedo R, Chiarugi A, Russi P, Lombardi G, Carlà V, Pellicciari R, Mattoli L, Moroni F 1994, Inhibitors of kynurenine hydroxylase and kynurenine increase cerebral formation of kynurenic acid and have sedative and anticonvulsant activities. Neuroscience 61:237.
3. Chiarugi A, Carpenedo R, Molina MT, Mattoli L, Pellicciari R, Moroni F (1995) Comparison of the neurochemical and behavioral effects resulting from the inhibition of kynurenine hydroxylase and/or kynureninase. J Neurochem in press.
4. Connick J, Lombardi G, Beni M, Moroni F (1988) Decrease in rat cerebral quinolinic acid concentration following hydrocortisone treatment. Neurosci Lett 88:216.
5. Connick J, Heywood GC, Sills GJ, Thomson GG, Brodie MJ, Stone TW (1992) Nicotinylalanine increases cerebral kynurenic acid content and has anticonvulsant activity. Gentile Pharmacol 23:235.
6. Decker RH, Brown RR, Price JM (1963) Studies on the biological activity of nicotynilalnine, an analogue of kynurenine. J Biol Chem 238:1049.
7. Dennison Z, Ossenkop KP, Cain DP (1992) Effects of central administration of kynurenic acid on spontaneous locomotor activity in kindled rat: a multivariate approach of using the automated Digiscan monitoring system. Pharmacol Biochem Behav 43:807.
8. Eastman CL, Guilarte TR (1989) Citotoxicity of 3-hydroxykynurenine in a neuronal hybrid cell line. Brain Res 495:225.
9. Heyes MP, Brew BJ, Martin A, Price RW, Salazar AM, Sidtis JJ, Yergey JA, Mouradian MM, Sadler AE, Keilp J, Rubinov D, Markey SP (1991) Quinolinic acid in cerebrospinal fluid and serum in HIV-1 infection: relationship to clinical and neurological status. Ann Neurol 29:202.
10. Moroni F, Lombardi G, Carlà V, Moneti G (1984a) The excitotoxin quinolinic acid is present and unevenly distributed in the rat brain. Brain Res 295:352.
11. Moroni F, Lombardi G, Moneti G, Aldinio C (1984b) The excitotoxin quinolinic acid is present in the brain of several animal species and its cortical content increases during the aging process. Neurosci Lett 47:51.
12. Moroni F, Lombardi G, Carlà V, Pellegrini D, Carassale GL, Cortesini C (1986) Content of quinolinic acid and of other tryptophan metabolites increases in brain regions of rats used as experimental models of hepatic encephalopathy. J Neurochem 46:869.
13. Moroni F, Russi P, Lombardi G, Beni M, Carlà V (1988) Presence of kynurenic acid in the mammalian brain. J Neurochem 51:177.
14. Moroni F, Russi P, Gallo-Mezo MA, Moneti G, Pellicciari R (1991) Modulation of quinolinic and kynurenic acid content in the rat brain: effects of endotoxins and nicotinylalanine. J Neurochem 57:1630.
15. Pellicciari R, Natalini B, Costantino G, Mahmoud MR, Mattoli L, Sadeghpour BM, Moroni F, Chiarugi A, Carpenedo R (1994) Modulation of the kynurenine pathway in search for new neuroprotective agents. Synthesis and preliminary evaluation of (m-nitrobenzoyl)alanine, a potent inhibitor of kynurenine-3-hydroxylase. J Med Chem 37:647.
16. Rogawski M (1992) The NMDA receptor, NMDA antagonists and epilepsy therapy. Drugs 44:279.
17. Russi P, Alesiani M, Lombardi G, Davolio P, Pellicciari R, Moroni F (1992) Nicotinylalanine increases the formation of kynurenic acid in the brain and antagonizes convulsions. J Neurochem 59:2076.
18. Saito K, Markey SP, Heyes MP (1992) Effects of immune activation on quinolinic acid and kynurenine pathway metabolism in the mouse. Neuroscience 51:25.
19. Saito K, Crowley JS, Markey SP, Heyes MP (1993a) A mechanism for increased quinolinic acid formation following acute systemic immune stimulation. J Biol Chem 268:15496.
20. Saito K, Nowak TSJ, Markey SP, Heyes MP (1993b) Mechanism of delayed increase in kynurenine pathway metabolism in damaged brain regions following transient cerebral ischemia. J Neurochem 60:180.
21. Sing L, Oles RJ, Tricklebank MD (1990) Modulation of seizure susceptibility in the mouse by the strychnine-insensitive glycine recognition site of the NMDA receptor/ion channel complex. Br J Pharmacol 99:285.
22. Stone TW (1993) Neuropharmacology of quinolinic and kynurenic acids. Pharmacol Rev 45:309.